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osting by EAbstract Gaucher disease is the most prevalent lysosomal storage diseases which results from
inherited deﬁciency in the glucocerebrosidase enzyme. Three main clinical forms have been
described: type I non-neuropathic, type II acute neuropathic and type III subacute neuropathic.
Although it is panethnic disease, its presentation has some ethnic speciﬁc characteristics. In this
work, we present speciﬁc characteristics as well as our experience in diagnosing and managing a
group of Egyptian patients with this disease. The study included 48 patients with Gaucher disease
attending Children’s Hospital, Ain Shams University. The recombinant enzyme imiglucerase
(cerezyme) was given in a dose of 60 U/kg/2 weeks. Haemoglobin, platelet count, plasma chitotri-
osidase, and abdominal ultrasound were assessed before starting therapy and every 6 months.
Molecular analysis was done to 23 patients. At presentation, the mean age was 2.54 ± 3.8 years.
Ten patients (20.8%) had type I, 6 had type II (12.5%) and 26 had type III Gaucher diseasehmed Amin Street, St. Fatima
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10 A.S. Khalifa et al.(66.7%). The commonest genotype was homozygous L444P which was present in 13 patients
(56.5%) followed by homozygous N370S; found in three patients (13.04%). Follow up after enzyme
replacement therapy revealed a signiﬁcant increase in weight and height, haemoglobin level and
platelet count and slow reduction in the liver span and spleen length. Bone manifestations showed
slow but complete improvement while neurological and respiratory manifestations were partially
ameliorated with individual variations. To conclude, since most of Egyptian children with GD have
type III disease and L444P/L444P genotype, a minimum dose of 60 U/kg/2 weeks should be main-
tained until adulthood. Higher doses started at an early age may delay the progression of neurolog-
ical symptoms. Pulmonary involvement is not rare in Egyptian patients and may respond to dose
increase or dose fractionation. Cardiovascular and renal involvement should be further studied
in our population.
 2011 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Gaucher disease (GD) is the most frequently encountered
lysosomal storage disease caused by inborn defects of the
membrane-bound lysosomal enzyme, acid b-glucosidase or
glucocerebrosidase. This defective activity causes an accumula-
tion of glucocerebrosidase in the lysosomes of cells derived
from the monocyte/macrophage lineage. Glucocerebrosidase-
engorged cells, termed Gaucher cells, inﬁltrate various organs,
leading to multisystem abnormalities [1]. GD is classiﬁed into
three main types based according to the presence and nature of
CNS involvement; type II (infantile type) has infantile onset of
severe CNS involvement and death in early childhood; and
type III has onset of mild CNS involvement in adolescence
or early childhood and has a more indolent course. The most
common form is type I (adult type), the age of onset and rate
of progression varies widely, ranging from disability in tod-
dlers to asymptomatic disease [2]. An atypical form of GD
(cardiovascular form) dominated by cardiovascular involve-
ment with calciﬁcation of the mitral and aortic valves has been
described by Bohlega et al. [3]. Additional manifestations may
include mild splenomegaly, corneal opacities, and supranu-
clear ophthalmoplegia [4]. A perinatal lethal form associated
with hepatosplenomegaly, pancytopenia that may present clin-
ically as ichthyosiform or collodion skin abnormalities or as
non-immune hydrops fetalis has been described by Orvisky
et al. [5]. Another rare severe variant of GD associated with
hydrocephalus, corneal opacities, deformed toes, gastroesoph-
ageal reﬂux, and ﬁbrous thickening of splenic and hepatic cap-
sules was described by Inui et al. [6].
In this study, we present the experience in diagnosis and
management of 48 Egyptian children with GD, attending the
Children’s Hospital, Ain Shams University.2. Patients and methods
The study included all patients with GD (48) diagnosed from
June 1995 to December 2006 in the Haematology and Genetics
Clinics, Children’s Hospital, Ain Shams University which is
the second largest university in Egypt and a tertiary referral
center.
2.1. Diagnosis
For all patients the following was done before starting therapy
and then every 6 months after starting therapy: Full history, three generation family pedigree construction
and thorough clinical examination laying stress on growth
parameters, pallor, bleeding manifestation, hepatospleno-
megaly and full cardiac and neurological examination.
 Laboratory investigations included complete blood count
(CBC) and reticulocyte count (anaemia and thrombocyto-
penia were deﬁned according to the age and sex speciﬁc val-
ues), prothrombin time (PT) and partial thromboplastin
time (PTT), liver function tests, renal function tests, bone
marrow aspirate (done only before starting therapy), liver
biopsy and/or splenic aspirate if needed.
 Radiological investigations included plain X-ray for long
bones and chest, abdominal ultrasonography to evaluate
liver and spleen volumes, echocardiography, DEXA scan
and MRI of femurs for selected patients.
 Measurement of plasma chitotriosidase and assessment of
b-glucosidase enzyme activity in peripheral leucocytes.
The chitotriosidase normal level ranges from 4 to 80
lmol/L/h [7]. Normal enzyme level ranges from 1 to
5 lmol/h/g protein [8].
 Analysis of common mutations was performed for 23
patients by PCR and full sequencing of GBA gene [9].
 Family screening was done in ﬁve families by measuring
b-glucosidase enzyme activity in peripheral leucocytes.
GD was detected in ﬁve sibs including two from one family.
 Prenatal diagnosis was done in two families and fetuses
proved to be normal.
2.2. Enzyme replacement therapy (ERT)
ERT started in 1997 using the placenta derived aglucerase
(ceredase) at low dose regimen (15 U/kg/2 weeks). Treatment
with the recombinant imiglucerase (cerezyme) began on March
1999 in a dose of 20–30 U/kg/month, divided into four equal
weekly doses. In this period, ERT was started in 17 patients
and discontinued in three patients: The ﬁrst patient was
3.5 years old and had advanced type I GD. He died 4 weeks
after the beginning of ceredase therapy of nephrotic syndrome
and progressive renal failure. The second patient had advanced
type III GD and died 2 months later with extensive broncho-
pneumonia. The third developed chronic myeloid leukemia
after 6 months of good response to ERT. Since the ﬁrst of July
1999, Cerezyme was administered in a high dose regimen of
60 U/kg/2 weeks for 48 patients. The protocol was approved
by Gaucher registry and informed consent was obtained from
the parents of all patients.
Outcome of enzyme replacement therapy in children with Gaucher disease 112.3. Statistical methods
Standard computer program SPSS for Windows, release 13.0
(SPSS Inc., USA) was used for data entry and analysis. All
numeric variables were expressed as mean ± standard devia-
tion (SD). Comparison of different variables in various groups
was done using Student’s t-test and Mann–Whitney test for
normal and non-parametric variables, respectively. Multiple
regression analysis was also performed to determine effect of
various factors on a dependent variable. For all tests a proba-
bility (p) less than 0.05 was considered signiﬁcant [10].
3. Results of patients on ERT
Patients’ ages at presentation ranged from 37 days to 16 years
with mean age of 2.54 ± 3.8 years. Male to female ratio was
3.5:1. Consanguinity between parents was present in 43 pa-
tients (88.8%). This included ﬁrst cousin’s marriage in 32 cases
(74.4% of consanguineous marriage), second cousins’ mar-
riage in ﬁve cases (11.6%) and remote consanguinity in six
cases (13.9%). Family history was positive in 26 patients
(54.16%).
Bone marrow aspiration was done to all patients and re-
vealed lipid engorged macrophages (Gaucher cells) in 40 of pa-
tients (83.3%). Liver biopsy was done in two patients and
splenic aspirate was done to ﬁve patients. All revealed typical
Gaucher cells. Splenectomy was done in three patients because
of hypersplenism before starting ERT therapy.
Plasma chitotriosidase activity was markedly increased in
all patients with mean of 1612.6 ± 2116.54–80 lmol/L/h.
Diagnosis was conﬁrmed by assessment of b-glucosidase en-
zyme activity in peripheral leucocytes which was decreased to
0–15% of normal values in all patients. It was the only diag-
nostic tool in nearly 17% of patients (in conditions when Gau-
cher cells could not be detected in bone marrow and during
screening of families of patients).
Initially, 29 patients had clinically type I GD (60.4%). With
follow up, neurological manifestations started to appear in 19
children and so they were re-categorized as type III GD. Also
two patients who were initially diagnosed as having type III
GD, proved later to have type II GD. Final diagnosis included
10 patients with type I GD (20.8%), 6 patients with type II GD
(12.5%) and 32 patients with type III GD (66.67%) (Fig. 1).0
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Figure 1 Patient distribution according to the diagnosis at
enrollment and ﬁnal diagnosis.Genotyping revealed that all of the type III patients tested
were homozygous for the L444P mutation (Table 1).
Follow up of the patients receiving ERT for 24 months re-
vealed a signiﬁcant increase in weight after 6 months of ERT
(p= 0.045) that was progressed after 12 months (p= 0.01),
18 months (p= 0.014) and not after 24 months (p= 0.084).
On the other hand, patients’ heights were gradually increasing
although statistically not signiﬁcant. At presentation haemo-
globin level (Hb) varied between 5 and 11 g/dL (mean
8.3 ± 1.5 g/dL). There was a signiﬁcant increase in Hb level
after ERT with no signiﬁcant difference between types I and
III. It is to be noted that GD patients usually become transfu-
sion independent after 2–3 doses of enzyme therapy. This is
unlike platelets count which was signiﬁcantly increased only
after 24 months of ERT (Table 2).
Plasma chitotriosidase levels showed signiﬁcant decrease
after 6 and 12 months of ERT assay with no signiﬁcant differ-
ence between types I and III GD. After 24 months its mean
level was 288 ± 309.7 lmol/L/h (Table 2). There was slow
reduction in ultrasound measures of liver span during the
24 months follow up period with no signiﬁcant difference be-
tween types I and III except in two patients who developed
progressive hepatomegaly as they developed viral hepatitis
type C. On the other hand, ultrasound splenic length showed
signiﬁcant reduction in the 24 months follow up period with
no signiﬁcant difference between types I and III GD. The re-
sponse to ERT was variable in different patients even in the
same phenotype in both the liver span and splenic length.
While there was mild improvement in motor development
and variable improvement of dysphagia (although at slower
rate than visceral improvement) on ERT, ophthalmoplegia
did not show signiﬁcant improvement in type III patients.
Individual variations were also observed in patients’ response
to ERT regarding neurological manifestations. Bone manifes-
tations showed very slow improvement on ERT that needed
more time to become evident but generally, all patients demon-
strated improvement in quality of life in an average of
6 months period.
Respiratory complications were present in seven patients
(14.6%). Six of them had moderate pulmonary inﬁltrate with
recurrent attacks of respiratory distress and wheezy chest and
one patient developed extensive pulmonary inﬁltrate that
needed recurrent ICU admission (type III GD, genotype
L444P/L444P) (Fig. 2). Renal manifestations were present in
two patients (5.56%), one had kidney stones (type III GD)
and the other had nephrotic syndrome (type I GD). CardiacTable 1 Phenotype/genotype of 23 patients of GD in this
study.
Phenotype Genotype No. %
Type I GD N370S/N370S 3 13.04
P266L/N370S 1 4.3
L444P/N370S 1 4.3
–/N370S 1 4.3
L444P/L444P 2 8.6
Type II GD P266L/P266L 1 4.3
Type III GD L444P/L444P 11 47.8
Cardiovascular form D409H/D409 H 3 13.04
Total 23 100
Table 2 Anthropometric and laboratory data in the studied patients after ERT.
Variable Initial 6 months 12 months 18 months 24 months
Mean ± SD Mean ± SD p value Mean ± SD p value Mean ± SD p value Mean ± SD p value
Weight (percentile SD) 2.1 ± 2.6 0.2 ± 3.6 0.045* 0.5 ± 2.5 0.01* 1.5 ± 3.1 0.014* 0.4 ± 3.6 0.08
Height (m) (percentile SD) 2.4 ± 3.1 1.3 ± 2.6 0.11 1 ± 2.3 0.059 0.8 ± 2.3 0.056 1.2 ± 2.8 0.26
Hb level (g/dL) 8.3 ± 1.5 9.2 ± 1.3 0.07 10.8 ± 1 0.00* 11.4 ± 1.3 0.00* 13 ± 1.4 0.00*
Platelet count (·103 mm3) 203 ± 216 147.7 ± 154 0.4 269 ± 219 0.08 259 ± 4216 0.15 249 ± 69 0.01*
Chitotriosidase (lmol/L/h) 1612 ± 2116 1312 ± 1634 0.04* 475 ± 191 0.03* 438 ± 236 0.07 288 ± 309.7 0.24
* p value <0.05 (signiﬁcant result).
Figure 2 CT chest showing centrilobular and subpleural nodules
with interlobular and septal thickening with prominent pulmonary
interstitium.
Figure 3 Echocardiography showing calciﬁed mitral and aortic
valves.
12 A.S. Khalifa et al.manifestations were present in six patients. Concentric left ven-
tricular hypertrophy and systemic hypertension was present in
one patient with type III GD. Two patients had pericardial
effusion and cardiomyopathy (one type I and one type III). Cal-
ciﬁcation of aortic and mitral valves and hypertrophy of inter-
ventricular septum were present in one patient cardiovascular
form (genotype: D409H/D409H) (Fig. 3). The last patient’s
younger brother had dilatation of both ventricles, thickened
right and left coronaries, thickening of the aortic valve and tri-
cuspid regurge. His younger sister had dilatation of ventricles,
mild pulmonary hypertension and early myopathy.
We tried to reduce the ERT dose from 60 to 45 U/kg/
2 weeks after 3 years of good response to therapy in four pa-
tients: the ﬁrst was a 16 year old girl with type I GD
(N370S/N370S) but she developed bone pains and osteoporo-
sis after 6 months of dose reduction and therefore bisphospho-
nates was added. The second was a 7 year old boy with
cardiovascular form (D409H/D409H) but he developed pro-
gressive splenomegaly and cerebral dysrhythmia (EEG ﬁnding)
and therefore the former dose was returned after 6 months.
The third was a 3.5 year old boy with type III (L444P/
L444P) but he developed status epilepticus after 4 months
and died. The fourth was a 7 year old boy with type III
(L444P/L444P). Although his hematological parameters werestable; he developed EEG changes after 1 year in the form of
epileptic activity with no convulsions.
On the other hand, we tried to increase ERT dose from 60
to 120 U/kg/2 weeks in two patients: the ﬁrst was a 2.8 year old
boy with type III (L444P/L444P) with extensive pulmonary
inﬁltrates, concentric left ventricular hypertrophy and recur-
rent admission to ICU. An improvement was noticed for few
months but after 9 months he died suddenly at home during
his sleep with unidentiﬁed cause. The second is a 7 year old
boy with type III (L444P/L444P) who was receiving ERT since
the age of 20 months and developed progressive neurological
manifestation and myoclonic ﬁts. The convulsions were con-
trolled after dose increase.
ERT was discontinued in three patients: the ﬁrst is a
4.5 year boy with type I (P266L/N370S) who had no response
after 1 year and his father decided to discontinue. The second
is a 6 year old boy who was initially diagnosed as type I GD
and had no response after 1 year of regular ERT. Reevaluation
revealed that he has Niemann-Pick type C disease. The third is
a 9 month old girl with type III GD who had no response after
1 year with progressive hepatosplenomegaly and neurological
manifestation. Reevaluation revealed that she had type II GD.
4. Discussion
In this study, most of our patients were of type III GD
(66.67%), which is different from what was found by the Inter-
Outcome of enzyme replacement therapy in children with Gaucher disease 13national Collaborative Gaucher group in which most patients
were of type I GD [11]. This may be due to inclusion of only
children with GD and not inclusion of adult group. The reclas-
siﬁcation of 19 patients of type I into type III emphasizes the
importance of careful follow up of neurological symptoms in
this population (especially that type III appears to be the most
common type) and indicates that the dose of 60 U/kg/2 weeks
do not prevent the progression of neurological disease
although it might delay its appearance.
Anemia in GD may result from haemolysis secondary to
hypersplenism, haemodilution, and splenic sequestration, and
in more advanced cases (particularly post-splenectomy), from
depressed erythropoiesis associated with Gaucher cells inﬁltra-
tion of the bone marrow. Thrombocytopenia occurs as a result
of hypersplenism, splenic pooling of platelets, and/or marrow
inﬁltration [12]. Improvement in hematologic cytopenias is
among the earliest and most sensitive indicators of response
to ERT [13]. In our patients, haemoglobin level varied between
5 and 11 g/dL (mean 8.3 ± 1.5 g/dL) at presentation. It in-
creased to normal or near normal within 6–12 months with a
sustained response through 18 and 24 months with no signiﬁ-
cant difference between types I and III GD patients. Patients
usually become transfusion independent after 2–3 doses of en-
zyme therapy. The same was true for platelet count. The same
observations were documented by the international Gaucher
registry [14].
The most common mutation found in this study was
L444P/L444P which was detected in 56.5% of patients while
N370S/N370S represented only 13.04% of mutations detected.
This is consistent with what was found in non-Jewish popula-
tion, as the most common mutations were L444P, N370S,
D409H, R463C and IVS+1 [15] and different from what
was reported by the International Collaborative Gaucher
group where N370S/N370S was the most common detected
mutation (29%) and L444P/L444P accounted for only 6%
for detected mutations [16]. This is because most of our pa-
tients were of type III GD in which homozygosity for the
L444P mutation was the most common genotype [17].
GD is characterized by considerable variability in its clini-
cal signs and symptoms. This phenotypic variability is ob-
served, even amongst siblings with the same genotype [18].
There is also signiﬁcant lack of understanding of how the
expression of the phenotype is modiﬁed by epigenetic and envi-
ronmental factors to affect disease expression and severity.
Some correlation has been observed between genotype and
phenotype in GD. However, prediction of organ involvement,
disease severity and rate of progression based on mutation
analysis is generally not possible, due to the extremely wide
variation in disease expression, even among speciﬁc ethnic
groups [17]. In the present study, there was no clear association
between genotype and phenotype. ERT response was also var-
iable even in same phenotype and genotype. It was evident that
genotype N370S is present in all patients with type I GD either
in the homozygous (50%) or heterozygous form (50%). its
presence usually ameliorates the clinical presentation and pro-
tects against the development of neurologic disease. On the
other hand, homozygote L444P was present in all patients with
type III disease. This is consistent with Grabowski study who
suggested that the homozygous N370S allele is usually associ-
ated with a generally less severe phenotype, although with wide
clinical variability. The heterozygous state for N370S is protec-
tive against CNS involvement; and the L444P allele in thehomozygous state is associated with early neurologic symp-
toms common in types II and III [19]. However in this study,
two children with homozygous L444P mutation (8.6%) exhib-
ited type I phenotype and they need careful observation as they
may develop neuropathic disease as they grow older. The same
was also previously reported in another Egyptian study [20].
Pulmonary involvement reported in GD includes interstitial
lung disease; alveolar/lobar consolidation; and pulmonary
hypertension [21,22]. In this study, respiratory complications
were present in seven patients (14.6%). Increasing the dose
to 120 U/kg/2 weeks showed initial improvement. On the other
hand, fractionation of the dose to 60 U/kg/week had better ef-
fect on one patient. Unfortunately follow up of this patient
could not be done as he died suddenly during his sleep few
months later.
We had one family in this study with three children with the
cardiovascular form (homozygous D409H). The older brother
had calciﬁcation of the mitral and aortic valves, the younger
brother had dilatation of both ventricles, thickened right and
left coronaries, thickening of the aortic valve and tricuspid reg-
urge while the youngest sister had dilatation of ventricles, mild
pulmonary hypertension and early myopathy. This again dem-
onstrates the variability of clinical presentation of the same
genotype. Cardiomyopathy and pericardial effusion was found
in two of our patients (one type I and one type III). Reports of
myocardium involvement in GD included decreased left ven-
tricular compliance with decreased cardiac output [23], wide
spread acute haemorrhagic necrosis of the left ventricular myo-
cardium with ﬁbrosis of coronary arteries and left ventricular
hypertrophy [24]. The effect of ERT on this problem still needs
follow up.
In our cohort, we had two other patients with renal prob-
lems; the ﬁrst had type I with nephritic syndrome in which
ERT did not stop the progression of his condition into renal
failure. The other had type III GD (L444P/L444P) with multi-
ple renal stones. Reports of nephritic syndrome in GD are few
with a well deﬁned glomerulopathy often with Gaucher cells in
the glomeruli [25]. Other reports included developmental de-
fects of the urinary system with bilateral megaureter and
hydronephrosis, developmental defects of the renal arteries,
and bilateral cystic renal dysplasia [26]. To the best of our
knowledge, kidney stones were not reported in GD before.
Severe bone disease was observed in two patients (in the
form of Erlenmeyer ﬂask shape deformity, bone fractures
and bone pains) and mild bone disease (bone aches) in one pa-
tient. They had dramatic improvement in the form of decreas-
ing bone aches and cessation of fractures but follow up is
essential. Although increased bone turnover rates are not pro-
ven, anti-osteoclastic therapy, primarily with bisphosphonates,
calcium and vitamin D has been suggested as an adjunctive
therapy for skeletal manifestations [27]. Treatment with bis-
phosphonates in the form of bonapex in a dose of 10 mg/day
was given as the only treatment in one patient with GD type
I and as adjuvant treatment to another two patients with type
I GD. All three patients had splenectomy before diagnosis.
However, in another Egyptian study ERT was effective in
ameliorating radiological manifestations of skeletal disease
and achieving complete remission of bone pains after
11.2 ± 4 months [20].
The safety proﬁle of imiglucerase is excellent. Only two pa-
tients developed allergic reactions with no antibodies detected.
The same was reported by Elstein and Zimran [28].
14 A.S. Khalifa et al.5. Conclusion
ERT with imiglucerase could improve the quality of life in pa-
tients with GD by ameliorating the GD associated anaemia,
thrombocytopenia, organomegaly, growth retardation and
bone pain. Since most Egyptian children with GD has type
III disease and L444P/L444P genotype, a minimum dose of
60 U/kg/2 weeks should be maintained until adulthood. Dose
reductions may cause early appearance of previously absent
neurological symptoms. Higher doses started at an early age
may delay the progression of neurological symptoms. Starting
dose of 90–120 U/kg/2 weeks particularly for younger patients
with normal intellect may be recommended.
Clinical variability exists in patients carrying the same geno-
type and between members of the same family. Pulmonary
involvement is not rare in Egyptian patients and may respond
to dose increase or dose fractionation. CVS and renal symp-
toms should be further studied in our population.
6. Disclosure statement
We declare that there are no conﬂicts of interests.
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